



# Panel Materials and CLE Information

## Panel Session Supporting Materials

---

### Panel Session One: IRA Drug Price Negotiation 201 - Strategic Implications and Key Open Questions

- [CMS Releases IRA Drug Price Negotiation Program Implementation Plan | Covington & Burling LLP](#)
- [Congress Passes Prescription Drug Pricing Reform | Covington & Burling LLP](#)

### Panel Session Two: Life Sciences Deals in 2023 - Key Trends in Capital Markets, M&A and Licensing

- [Endpoints News: Biopharma Venture Funding Fall to the Lowest Total Since 2019 as Startups Ponder Alternative Paths](#)
- [RA Capital Article: Semper Maior - Time to Reboot Biotech](#)
- [Life Sci VC Blog Post: Biotech Funding - Times are Tough, Maybe for the Better](#)
- [PDF of Torreya of Biopharma Market Update](#)

### Panel Session Three: Precision Medicine - Strategic Considerations in Drug-Diagnostic Collaborations

- [FDA Draft Guidance - Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product](#)
- [In Vitro Companion Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff](#)
- [FDA's List of Cleared or Approved Companion Diagnostic Devices \(In Vitro and Imaging Tools\)](#)

## CLE Credit

---

This program is approved for 1.0 Professional Practice (Transitional & Non-Transitional) credits in New York and 0.75 General credits in California. Uniform Certificates of Attendance can also be provided for those barred in other jurisdictions.